Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes

Study:

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)

Rationale:

n/a

Purpose:

This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2 diabetes receiving standard of care.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Renal Insufficiency, Chronic
Diabetes Mellitus, Type 2
Drug: Placebo
Drug: Bardoxolone Methyl: 20 mg
Phase 3

Verified by Reata Pharmaceuticals, Inc. October, 2012

Sponsored by: Reata Pharmaceuticals, Inc.
Information provided by: Reata Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT01351675

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site